The verdict
Our read at a glance.
Whether a four-amino-acid peptide restores pancreatic function in ageing, on evidence that has never left one research programme.
- The signal
- The animal work is more substantial than for most of this family and is internally consistent. Published studies report correction of impaired glucose tolerance in old female rats, effects on the differentiation of pancreatic cells during ageing, changes in blood glucose, capillary permeability and adhesion, and effects on endocrine pancreatic function in old monkeys, alongside broader work on tissue-specific stimulation of cell differentiation during ageing and characterisation of the Lys-Glu-Asp-Trp tetrapeptide's biological activity. What is missing is independence and translation: the work traces overwhelmingly to a single research programme, and there is no controlled human trial of any endpoint.
- The unknown
- Whether any of it replicates outside the originating group, and whether a tetrapeptide administered to a person survives to reach the tissue at all.
- Our read
- The most data-rich member of the bioregulator family on this Watchlist, which mainly demonstrates how far that is from being enough. A coherent animal literature from one group, no independent replication, and no human trial - and the claim being made is about blood glucose, which is a thing people already have real medicines for.
The mechanism
How it works.
Pancragen is the synthetic tetrapeptide Lys-Glu-Asp-Trp, one of the short peptides from the Russian bioregulator programme. The proposed mechanism is the one shared across that family: because the molecule is very small, it is said to enter cells and reach the nucleus, where it binds specific regions of DNA and shifts the expression of genes governing differentiation and function in a particular tissue - in this case pancreatic islet cells. On that account it is not replacing a hormone or blocking a receptor, but changing which genes an ageing cell reads, restoring a more youthful pattern of function. The evidence for that mechanism comes from cell culture, organotypic tissue models and animal studies within the originating research programme, and the fundamental translation question - whether an orally or parenterally administered tetrapeptide survives, distributes to the pancreas and enters nuclei in a person - has not been demonstrated in humans.
Safety & regulatory boundary
The consequential part.
Not approved as a medicine in the United States or European Union and not a lawful dietary supplement ingredient. Sold as a research or supplement product with no regulatory manufacturing standard behind identity, purity or dose. Because the claimed mechanism involves altering gene expression in pancreatic tissue, the absence of human safety data is a substantive gap rather than a formality.
What's next
What we're watching.
Independent replication outside the originating programme, which is the single thing that would change this read.
Context
Why this is discussed.
It is sold as a metabolic bioregulator to people managing blood sugar and ageing, and the animal findings sound specific enough to be persuasive.
The evidence base
9 cited references.
Indexed literature (PubMed)9
Korkushko OV et al. · Bull Exp Biol Med · 2011
Khavinson VKh et al. · Bull Exp Biol Med · 2013
Goncharova ND et al. · Adv Gerontol · 2015
Khavinson VKh et al. · Bull Exp Biol Med · 2007
Goncharova ND et al. · Adv Gerontol · 2014
Khavinson VKh et al. · Bull Exp Biol Med · 2012
Zakutskiĭ AN et al. · Adv Gerontol · 2006
Khavinson VKh et al. · Bull Exp Biol Med · 2010
Khavinson VKh et al. · Adv Gerontol · 2012
Keep reading